59089-67-7

Usage

Uses

Used in Pharmaceutical Industry:
2',4'-difluoro[1,1'-biphenyl]-4-yl acetate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with enhanced properties. The fluorine atoms can improve the pharmacokinetics and pharmacodynamics of the resulting compounds, while the acetate group allows for further functionalization.
Used in Agrochemical Industry:
In the agrochemical sector, 2',4'-difluoro[1,1'-biphenyl]-4-yl acetate is utilized as a building block for the creation of novel agrochemicals. Its unique structure can lead to the development of more effective and targeted pesticides or herbicides, potentially increasing crop yields and reducing environmental impact.
Used in Organic Synthesis:
2',4'-difluoro[1,1'-biphenyl]-4-yl acetate is employed as a versatile compound in organic synthesis, where its acetate functional group can be easily manipulated to produce a range of derivatives. This adaptability makes it suitable for the preparation of complex organic molecules and materials with specific applications in various fields.
Safety Precautions:
As with all chemicals, 2',4'-difluoro[1,1'-biphenyl]-4-yl acetate requires proper handling and adherence to safety protocols to minimize potential hazards or risks associated with its use. This includes appropriate storage, handling procedures, and protective measures to ensure the safety of those working with the compound.

Upstream product

• 37847-52-2 2,4-difluorobiphenyl 
• 108-24-7 acetic anhydride 
• 33527-94-5 4-acetoxyiodobenzene 
• 144025-03-6 2,4-difluorophenylboronic acid 
• 540-38-5 p-Iodophenol 
• 53591-79-0 1-(2',4'difluoro[1,1']biphenyl-4-yl)ethanone 
• 64-19-7 acetic acid 

Downstream Products

• 22494-42-4 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid 
• 59089-68-8 4-(2,4-difluorophenyl)-phenol 

Relevant academic research and scientific papers

Acetoxyphenyl compound (by machine translation)

PROBLEM TO BE SOLVED: To provide a method for producing an acetoxyphenyl compound of high purity without using highly dangerous high-concentration (for example, 30 wt.% or more) peracetic acid and a halogen-based solvent which is avoided due to environmental problems in the production of an acetoxyphenyl compound by oxidation of an acetylphenyl compound.SOLUTION: There is provided a method for producing an acetoxyphenyl compound which comprises: a step of dissolving a hydrogen sulfate in at least one of the following (a) to (c); and a step of mixing (a) to (c) to oxidize an acetoxyphenyl compound: (a) an aromatic hydrocarbon solution of an acetylphenyl compound, (b) acetic acid or an acetic acid aqueous solution, and (c) hydrogen peroxide water.

Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of Amyloidogenesis

Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibril formation. High inhibitory activity was observed for 26 of the compounds. Of those, eight exhibited excellent binding selectivity for TTR in human plasma (binding stoichiometry > 0.50, with a theoretical maximum of 2.0 inhibitors bound per TTR tetramer). Biophysical studies reveal that these eight inhibitors dramatically slow tetramer dissociation (the rate-determining step of amyloidogenesis) over a duration of 168 h. This appears to be achieved through ground-state stabilization, which raises the kinetic barrier for tetramer dissociation. Kinetic stabilization of WT TTR by these eight inhibitors is further substantiated by the decreasing rate of amyloid fibril formation as a function of increasing inhibitor concentration (pH 4.4). X-ray cocrystal structures of the TTR·182 and TTR·202 complexes reveal that 18 and 20 bind in opposite orientations in the TTR binding site. Moving the fluorines from the meta positions in 18 to the ortho positions in 20 reverses the binding orientation, allowing the hydrophilic aromatic ring of 20 to orient in the outer binding pocket where the carboxylate engages in favorable electrostatic interactions with the ε-ammonium groups of Lys 15 and 15′. The hydrophilic aryl ring of 18 occupies the inner binding pocket, with the carboxylate positioned to hydrogen bond to the serine 117 and 117′ residues. Diflunisal itself appears to occupy both orientations based on the electron density in the TTR·12 structure. Structure-activity relationships reveal that para-carboxylate substitution on the hydrophilic ring and dihalogen substitution on the hydrophobic ring afford the most active TTR amyloid inhibitors.